Trials / Terminated
TerminatedNCT00479167
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodg
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Rush University Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine what dose of bortezomib in combination with tositumomab I-131 is tolerable whether bortezomib and Tositumomab I-131 are effective in the treatment of relapsed or refractory non-hodgkin's lymphoma (NHL). Both agents are effective in treating relapsed and refractory NHL. Administer of the agents together may sensitize the cells to the radiation from Tositumomab I-131.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bortezomib and Tositumomab I-131 |
Timeline
- Start date
- 2007-05-01
- Primary completion
- 2008-09-01
- Completion
- 2008-09-01
- First posted
- 2007-05-28
- Last updated
- 2021-11-04
- Results posted
- 2021-11-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00479167. Inclusion in this directory is not an endorsement.